The aim of this 12-week randomized multicenter double-blind parallel group placebo-controlled dose finding study is to assess the efficacy and safety of three different doses of LC350189 in subjects with hyperuricemia and a diagnosis of gout.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
156
Xanthine Oxidase Inhibitor
Matching placebo
Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84
sUA level was measured at Day 84
Time frame: Day 84
Percentage of Participants With sUA (Serum Uric Acid) < 6.0 mg/dL at Day 84
sUA level was measured at Day 84
Time frame: Day 84
Maximum Percent Reduction in sUA (Serum Uric Acid) Level
sUA level was measured at Day 1, 14, 28, 56, and 84
Time frame: Up to Day 84
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Synexus Clinical Research
Birmingham, Alabama, United States
Synexus Clinical Research
Chandler, Arizona, United States
Synexus Clinical Research
Mesa, Arizona, United States
Synexus Clinical Research
Tucson, Arizona, United States
Preferred Research Partner
Little Rock, Arkansas, United States
Health Awareness Inc
Jupiter, Florida, United States
Meridien Research
Maitland, Florida, United States
Miami Dade Medical Research Institute
Miami, Florida, United States
Meridien Research
St. Petersburg, Florida, United States
Clinical Research Trials of Florida, Inc
Tampa, Florida, United States
...and 24 more locations